WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/037322    International Application No.:    PCT/JP2004/015221
Publication Date: 28.04.2005 International Filing Date: 15.10.2004
Chapter 2 Demand Filed:    11.08.2005    
A61K 31/409 (2006.01), A61K 35/76 (2006.01)
Applicants: THE NEW INDUSTRY RESEARCH ORGANIZATION [JP/JP]; 1-5-2, Minatojima-minamimachi, Chuo-ku, Kobe-shi, Hyogo 6500047 (JP) (For All Designated States Except US).
GOTO, Akinobu [JP/JP]; (JP) (For US Only).
HAMADA, Katsuyuki [JP/JP]; (JP) (For US Only).
SHIRAKAWA, Toshiro [JP/JP]; (JP) (For US Only)
Inventors: GOTO, Akinobu; (JP).
HAMADA, Katsuyuki; (JP).
SHIRAKAWA, Toshiro; (JP)
Agent: TSUBURAYA, Toru; Osaka Ekimae Dai-3 Bldg. Room 1616, 1-1-3, Umeda Kita-ku, Osaka-shi Osaka 5300001 (JP)
Priority Data:
2003-354983 15.10.2003 JP
(JA) 癌遺伝子治療薬
Abstract: front page image
(EN)An oncogene therapeutic drug which contains a carrier cell having been infected with an oncolytic virus so as to treat a tumor cell with the virus within the living body. As the carrier cell, any of an A549 cell, a 293 cell, an SW626 cell and an HT-3 cell showing a potent antitumor effect is used. Because of using such a cell having a high antitumor effect both in vitro and in vivo as the carrier cell, an enhanced antitumor effect can be established compared with conventional carrier cells.
(FR)L'invention concerne un médicament de traitement anticancéreux contenant une cellule vectrice qui a été infectée par un virus oncolytique de manière à pouvoir traiter une cellule tumorale, au moyen du virus, dans un corps vivant. Une cellule de type A549, 293, SW626 ou HT-3 présentant un effet antitumoral puissant peut être utilisée en tant que cellule vectrice. L'utilisation d'une cellule présentant un effet antitumoral puissant, à la fois in vitro et in vivo, en tant que cellule vectrice permet d'obtenir un effet antitumoral accru par rapport celui de cellules vectrices traditionnelles.
(JA) 本発明の癌遺伝子治療薬は、オンコリティックウイルスを感染させ、同ウイルスを腫瘍細胞に作用させるためのキャリアー細胞を含み、当該キャリアー細胞には、強力な抗腫瘍効果が認められたA549細胞、293細胞、SW626細胞、HT—3細胞のいずれかが使用される。本発明は、in vitroおよびin vivoの双方において高い抗腫瘍効果が認められたこれらの細胞をキャリアー細胞として用いているので、従来のキャリアー細胞に比べて強力な抗腫瘍効果を得ることができる。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)